The American Medical Association and RAND Corp. release findings from a study assessing how physicians view new pay models. Also this week, earnings season continues.
A treatment that boosts the immune system greatly improved survival in people newly diagnosed with the most common form of lung cancer. It's the biggest win so far for immunotherapy, which has had much of its success in less common cancers.
Despite losing market exclusivity for a few of its drugs, Merck & Co. beat analysts' earnings predictions with first-quarter pharmaceutical sales rising by 1%.
Merck & Co.'s new cancer medicine Keytruda, a blockbuster nearly overnight, along with aggressive and ongoing cost cuts, helped to boost the company's fourth-quarter profits by 21%.
Inspired in part by the meth campaign, the hospital jolted parents—and stirred up plenty of criticism— with TV ads and billboards featuring pictures of overweight children, many with messages that subtly criticized parents. One, for example, said, “Big bones didn't make me this...
Doctors have found a disturbing downside to some powerful new drugs that harness the immune system to fight cancer. In rare cases, they may cause potentially fatal heart damage, especially when used together.
Higher sales of vaccines and prescription medicines, coupled with restrained spending, helped Merck & Co. post a 20% jump in third-quarter profit, trouncing Wall Street expectations.
Merck & Co. lowered its financial forecasts for 2016, citing higher restructuring and other costs, despite a big jump in second-quarter profit.
Drugmaker Merck and Premier, the GPO and performance improvement company, are teaming up to develop app-based solutions to assist providers in improving their population health outcomes.
Drugmaker Merck & Co. is buying Afferent Pharmaceuticals, a privately held biotechnology company developing a chronic cough medication.
Balancing innovation with the rising costs of therapies and value-based payment models is top of mind this week at the largest annual gathering of oncologists.
Michael Garfield has been named senior VP and CEO at Mercy Health Cincinnati. He takes over for John Starcher, who last month was named incoming president and CEO for parent system Mercy Health, also in Cincinnati.